 This is a multi-centre Phase III randomized controlled study of patients with multiple myeloma MM. Eligible patients who are not candidates for transplantation will be randomized to receive eight courses of MelphalanPrednisolone with or without Thalidomide treatment. Thalidomide will be initiated at the dose of 100 mgday and maintained at 100 mgday. The patients will be assessed for any responses at the end of 2nd, 4th, 6th and 8th cycles of treatment. The toxicities will be assessed at monthly intervals. Patients will be assessed for the: 